¼¼°èÀÇ °æ±¸ ¾à¹°Àü´Þ ½ÃÀå
Oral Drug Delivery
»óǰÄÚµå : 1792808
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 498 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License)
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)


Çѱ۸ñÂ÷

°æ±¸ ¾à¹°Àü´Þ ¼¼°è ½ÃÀåÀº 2030³â±îÁö ¹Ì±¹¿¡¼­ 1,801¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1,258¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â °æ±¸ ¾à¹°Àü´Þ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 6.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1,801¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Á¤Á¦´Â CAGR 4.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 726¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ĸ½¶Á¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 7.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 343¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ °æ±¸ ¾à¹°Àü´Þ ½ÃÀåÀº 2024³â¿¡ 343¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 363¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 9.5%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.1%¿Í 6.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ °æ±¸ ¾à¹°Àü´Þ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°æ±¸ ¾à¹°Àü´ÞÀÌ Àü½Å ¿ä¹ýÀ¸·Î ¼±ÅõǴ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

°æ±¸ ¾à¹°Àü´ÞÀº Æí¸®¼º, ºñħ½À¼º, ºñ¿ë È¿À²¼º ¶§¹®¿¡ ÀǾàǰÀÇ Åõ¿© °æ·Î·Î °¡Àå ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÚ°¡ Åõ¿©¸¦ Áö¿øÇϰí, ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½Ã۸ç, ±¤¹üÀ§ÇÑ ¾à¹°±º¿¡¼­ ÀϰüµÈ Àü½Å ³ëÃâÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Á¤Á¦, ĸ½¶Á¦, ¾×Á¦, ºÐ¸»Á¦°¡ Ç¥ÁØ Á¦ÇüÀ̸ç, ¹æÃâ Á¦¾î ¹× ºÎÀ§º° ½Ã½ºÅÛÀ» ÅëÇØ Ä¡·á ¼ºÀûÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

ÀÌ °æ·Î´Â ´ç´¢º´, °íÇ÷¾Ð, ½ÉÇ÷°üÁúȯ, ½Å°æ Áúȯ, °¨¿°¼º Áúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ °ü¸®¿¡ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù. ¸¹Àº ¿ø·áÀǾàǰ¿¡¼­ °æ±¸ Åõ¿©´Â ÃæºÐÇÑ »ýüÀÌ¿ë·ü, ¿¹Ãø °¡´ÉÇÑ Èí¼ö ÇÁ·ÎÆÄÀÏ, ½¬¿î Á¦Çü È®À强À» Á¦°øÇÕ´Ï´Ù. ±× °á°ú, °æ±¸ Åõ¿©´Â ÀϹÝÀǾàǰ°ú Àå±â ó¹æ ¿ä¹ý ¸ðµÎ¿¡¼­ ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.

°æ±¸ Àü´ÞÀÇ ¼º´ÉÀ» Çâ»ó½ÃŰ´Â ±â¼ú Çõ½ÅÀ̶õ?

¾à¹° Á¦Á¦ÀÇ ±â¼úÀû ¹ßÀüÀº ³·Àº ¿ëÇØµµ, ³·Àº ħÅõ¼º, ù ¹øÂ° Åë°ú ´ë»ç µî ±âÁ¸ÀÇ À庮À» ±Øº¹Çϰí ÀÖ½À´Ï´Ù. °íü ºÐ»ê, ÀÚ±â À¯È­ ½Ã½ºÅÛ, ³ª³ë ĸ½¶È­, °íºÐÀÚ ±â¹Ý ij¸®¾î µîÀÇ ±â¼úÀº ³­¿ë¼º ¾à¹°ÀÇ »ýü ÀÌ¿ë·üÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Àå¿ë¼º ÄÚÆÃ°ú Á¡Âø¼º Ç÷§ÆûÀº Ç¥Àû¿¡ ´ëÇÑ Àü´Þ°ú À§Àå¿¡¼­ÀÇ ºÐÇØ·ÎºÎÅÍÀÇ º¸È£¸¦ º¸ÀåÇÕ´Ï´Ù.

¼­¹æÇü Á¤Á¦ ¹× »ïÅõ¾Ð ÆßÇÁ Á¦Á¦¸¦ Æ÷ÇÔÇÑ ¼­¹æÇü ½Ã½ºÅÛÀº Àå±â°£¿¡ °ÉÃÄ ¾à¹° ¼öÁØÀ» Áö¼Ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ´ÙÀÔÀÚ Á¤Á¦ ¹× ±¸°­ºØÇØ Á¤Á¦´Â ƯÈ÷ ¼Ò¾Æ ¹× ³ë³âÃþ¿¡¼­ Åõ¿©ÀÇ À¯¿¬¼ºÀ» ³ô¿´½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î ºÎÇüÁ¦ ±â¼ú°ú 3D ÇÁ¸°ÆÃÀº °³º°È­µÈ ¿ë·®ÀÇ ¸ÂÃãÈ­¸¦ ¿ëÀÌÇÏ°Ô ÇÏ¿© °æ±¸¿ë Á¦Á¦¿¡¼­ Á¤¹Ð ÀÇ·áÀÇ ºÎ»óÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

¼ö¿ä´Â ¾îµð¿¡¼­ È®´ëµÇ°í ÀÖÀ¸¸ç, ¾î¶² Ä¡·á ºÎ¹®ÀÌ »ç¿ëÀ» ÁÖµµÇϰí Àִ°¡?

°æ±¸¿ë ¾à¹°Àü´Þ¿¡ ´ëÇÑ ¼ö¿ä´Â ¼±Áø±¹°ú ½ÅÈï±¹ ½ÃÀå¿¡¼­ ¸ðµÎ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ¸¸¼ºÁúȯ °ü¸®¿Í ÀçÅÃÀÇ·á ºÐ¾ß¿¡¼­ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù. ¼øÈ¯±â°è, ´ë»ç°è, Á¤½Å°ú ¾àǰÀº ¿©ÀüÈ÷ °æ±¸¿ë Á¦Á¦ÀÇ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¾Ï ºÐ¾ß¿¡¼­µµ ƯÈ÷ Áö¼ÓÀûÀÎ Åõ¿©°¡ ÇÊ¿äÇÑ Ç¥Àû Ä¡·áÁ¦¿¡ °æ±¸¿ë ¾à¹°ÀÌ Ã¤Åõǰí ÀÖ½À´Ï´Ù. Ç×°¨¿°Á¦, À§Àå¾à, È£¸£¸ó ¿ä¹ýµµ °æ±¸¾à¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù.

¼Ò¾Æ ¹× ³ëÀÎ Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ ¹Ì´Ï Á¤Á¦, ÇâÀÌ Ã·°¡µÈ Çöʾ×, Ãò¾îºí ŸÀÔ µî »õ·Î¿î °æ±¸¿ë Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾Ï ºÐ¾ß¿¡¼­´Â °æ±¸¿ë Ç¥Àû Ä¡·áÁ¦³ª È£¸£¸óÁ¦°¡ ¿Ü·¡ Ä¡·á¸¦ Áö¿øÇϰí ÀÖÀ¸¸ç, Á¤¸ÆÁÖ»çÀÇ Çʿ伺À» ÁÙ¿©ÁÖ°í ÀÖ½À´Ï´Ù. ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­ °æ±¸¿ë ¾àǰÀº º¸°ü ¹× Åõ¿©°¡ ¿ëÀÌÇϱ⠶§¹®¿¡ ´ë±Ô¸ð °øÁß º¸°Ç À¯ÅëÀ» Áö¿øÇÕ´Ï´Ù.

°æ±¸ ¾à¹°Àü´Þ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

°æ±¸¿ë ¾à¹°Àü´Þ ½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, Á¦Çü °úÇÐÀÇ ¹ßÀü, ºñħ½ÀÀû ÀÚ°¡ Åõ¿© ¿ä¹ý¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¿ëÇØ¼º Çâ»ó°ú ¹æÃâ Á¦¾î ±â¼úÀÇ ¹ßÀüÀ¸·Î Ä¡·á È¿°ú¿Í ȯÀÚ ¼øÀÀµµ°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

¾Ï Ä¡·á ¹× Àå±â °¨¿° Ä¡·á¿¡¼­ °æ±¸¿ë Ç¥Àû Ä¡·áÁ¦ÀÇ Ã¤ÅÃÀº ¾à¹°ÀÇ ¾ÈÁ¤¼º, »ýü ÀÌ¿ë·ü, ¼ÒÈ­°ü Ÿ°ÙÆÃ¿¡ ´ëÇÑ ÅõÀÚ¿¡ ÈûÀÔ¾î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀǾàǰ »ý»ê È®´ë¿Í ´Ù¾çÇÑ ÀûÀÀÁõ¿¡ ´ëÇÑ °æ±¸¿ë ÀǾàǰ¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ Áõ°¡´Â ¼¼°è ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ Ä£È­ÀûÀÌ°í ¼øÀÀµµ°¡ ³ôÀº ¾à¹°Àü´Þ ÇüÅ¿¡ ´ëÇÑ ¼ö¿ä´Â Çö´ë ¾à¹° Ä¡·á¿¡¼­ °æ±¸¿ë ½Ã½ºÅÛÀÇ Áö¼ÓÀûÀÎ ¿ªÇÒÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÇüÅÂ(Á¤Á¦, ĸ½¶Á¦, µå·ÓÁ¦, ¾×Á¦, ½Ã·´Á¦), À¯Çü(¹æÃâ Á¦¾îÁ¤, ±¸°­³» ºÐ»êÁ¤, ±âŸ À¯Çü), Ä¡·á ºÐ¾ß(Á¾¾ç Ä¡·á ºÐ¾ß, ±Ù°ñ°Ý°è Ä¡·á ºÐ¾ß, ¸é¿ªÄ¡·á ¿µ¿ª, ¼ÒÈ­±â Ä¡·á ºÐ¾ß, È£Èí±â Ä¡·á ºÐ¾ß, ½ÉÇ÷°ü°è Ä¡·á ºÐ¾ß, ±âŸ Ä¡·á ºÐ¾ß), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, Áø´Ü ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, Áø·á¼Ò ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Oral Drug Delivery Market to Reach US$180.1 Billion by 2030

The global market for Oral Drug Delivery estimated at US$125.8 Billion in the year 2024, is expected to reach US$180.1 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Tablets Form, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$72.6 Billion by the end of the analysis period. Growth in the Capsules Form segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$34.3 Billion While China is Forecast to Grow at 9.5% CAGR

The Oral Drug Delivery market in the U.S. is estimated at US$34.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$36.3 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Oral Drug Delivery Market - Key Trends & Drivers Summarized

Why Is Oral Drug Delivery the Preferred Route for Systemic Therapy?

Oral drug delivery remains the most widely used route for administering pharmaceuticals due to its convenience, non-invasiveness, and cost-effectiveness. It supports self-administration, improves patient compliance, and allows for consistent systemic exposure across a wide range of drug classes. Tablets, capsules, liquids, and powders are standard formats, with controlled-release and site-specific systems enhancing therapeutic outcomes.

This route is commonly used in managing chronic conditions such as diabetes, hypertension, cardiovascular disorders, neurological diseases, and infectious illnesses. For many APIs, oral delivery provides sufficient bioavailability, predictable absorption profiles, and easy formulation scalability. As a result, it continues to be the preferred choice for both over-the-counter medications and long-term prescription therapies.

What Technological Innovations Are Enhancing Oral Delivery Performance?

Technological advancements in drug formulation are overcoming traditional barriers such as poor solubility, low permeability, and first-pass metabolism. Techniques like solid dispersion, self-emulsifying systems, nanoencapsulation, and polymer-based carriers are improving bioavailability of poorly soluble drugs. Enteric coatings and mucoadhesive platforms are ensuring targeted delivery and protection against gastric degradation.

Modified-release systems, including extended-release tablets and osmotic pump formulations, are enabling sustained drug levels over longer durations. Multiparticulate and orally disintegrating tablets are enhancing dosing flexibility, especially in pediatric and geriatric populations. New excipient technologies and 3D printing are also facilitating personalized dose customization, supporting the rise of precision medicine in oral formulations.

Where Is Demand Expanding and Which Therapeutic Segments Lead Usage?

Demand for oral drug delivery is increasing in both developed and emerging markets, particularly in chronic disease management and home-based care. Cardiovascular, metabolic, and psychiatric drugs remain key drivers of oral formulation demand. Oncology is also adopting oral drugs for targeted therapy, especially where continuous dosing is required. Anti-infectives, gastrointestinal medications, and hormone therapies also rely heavily on oral formats.

Pediatric and geriatric populations are spurring demand for novel oral delivery options such as mini-tablets, flavored suspensions, and chewable formats. In oncology, oral targeted therapies and hormonal agents are supporting outpatient care, reducing the need for infusion visits. In low-resource settings, oral formats support large-scale public health distribution due to their ease of storage and administration.

Growth in the Oral Drug Delivery market is driven by several factors…

Growth in the oral drug delivery market is driven by factors such as the rising prevalence of chronic diseases, improvements in formulation science, and increased preference for non-invasive, self-administered therapies. Advancements in solubility enhancement and controlled-release technologies are enabling better therapeutic efficacy and patient adherence.

Adoption of oral targeted drugs in oncology and long-term infectious disease treatment is expanding, supported by investments in drug stability, bioavailability, and gastrointestinal targeting. Expanding pharmaceutical production in Asia-Pacific and increasing regulatory approvals for oral formulations across diverse indications are further supporting global market growth. Demand for patient-friendly, compliance-oriented drug delivery formats is reinforcing the sustained role of oral systems in modern pharmacotherapy.

SCOPE OF STUDY:

The report analyzes the Oral Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Form (Tablets Form, Capsules Form, Drops Form, Liquid or Syrup Form); Type (Controlled Release, Orodispersible Tablets, Other Types); Therapy Area (Oncology Therapy Area, Musculoskeletal Therapy Area, Immunology Therapy Area, Gastrointestinal Therapy Area, Respiratory Therapy Area, Cardiovascular Therapy Area, Other Therapy Areas); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Diagnostic Centers End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â